Factor VIII (FVIII) mimetics are engineered bispecific antibodies designed to treat hemophilia A by mimicking the function of missing factor VIII, specifically bridging activated factor IX (FIXa) and factor X (FX) to promote clotting.
They allow for subcutaneous administration and infrequent dosing, and remain effective in patients with inhibitors.
Key Factor VIII Mimetics: Emicizumab (Hemlibra): The first approved bispecific antibody, designed to treat hemophilia A by binding to FIXa and FX.
Mim8 (denecimig): A second-generation, next-generation bispecific antibody currently in phase 3 trials, aiming for higher potency and lower dosing frequency.
IN08: An investigational oral mimetic smaller in size that binds to serum albumin to prolong its half-life.
Mechanism: These antibodies mimic the FVIIIa co-factor function, bringing FIXa and FX together to facilitate FX activation and improve thrombin generation.
Administration: Subcutaneous (s.c.) injection, often with weekly, every-two-week, or monthly dosing schedules.
Inhibitors: These therapies are not affected by FVIII antibodies (inhibitors), overcoming a significant challenge in traditional factor replacement therapy.
Thrombosis Risk: Risk of thrombotic events exists, especially when used in combination with activated prothrombin complex concentrate (aPCC).
Effectiveness: Studies show high effectiveness in reducing bleed rates in hemophilia A patients.